VERTEX PHARMACEUTICALS INC / MA Increase (Decrease) in Restricted Cash and Investments
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Increase (Decrease) in Restricted Cash and Investments of $7.90 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-02-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments · last filed 2021-02-11
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash and investments for the quarter ending 2018-12-31 was $7.90M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash and investments for the quarter ending 2017-12-31 was $0.00, a 100.00% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash and investments for the quarter ending 2017-09-30 was $44.74M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash and investments for the quarter ending 2017-06-30 was $20.06M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash and investments for fiscal 2018 was $7.90M, a 87.18% decline from fiscal 2017.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash and investments for fiscal 2017 was $61.60M.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash and investments for fiscal 2016 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA increase (decrease) in restricted cash and investments for fiscal 2015 was -$11.69M.
| Period end | Increase (Decrease) in Restricted Cash and Investments 3 month | Increase (Decrease) in Restricted Cash and Investments 3 month as first filed | Increase (Decrease) in Restricted Cash and Investments 6 month | Increase (Decrease) in Restricted Cash and Investments 9 month | Increase (Decrease) in Restricted Cash and Investments 9 month as first filed | Increase (Decrease) in Restricted Cash and Investments 12 month | Increase (Decrease) in Restricted Cash and Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2018-12-31 | $7.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $7.90M 10-K · filed 2021-02-11 | |||||
| 2018-09-30 | $0.00 10-Q · filed 2018-10-25 | ||||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $44.74M derived: sum of 2 quarters · filed 2020-02-13 | $64.80M derived: sum of 3 quarters · filed 2020-02-13 | $61.60M 10-K · filed 2020-02-13 | $15.33M 10-K · filed 2018-02-15 | ||
| 2017-09-30 | $44.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-25 | $64.80M derived: sum of 2 quarters · filed 2018-10-25 | $61.60M 10-Q · filed 2018-10-25 | $15.64M 10-Q · filed 2017-10-30 | $82.09M derived: sum of 4 quarters · filed 2019-02-13 | ||
| 2017-06-30 | $20.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | $16.86M 10-Q · filed 2017-07-28 | $37.35M derived: sum of 3 quarters · filed 2019-02-13 | $25.26M derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2017-03-31 | -$3.20M 10-Q · filed 2017-04-28 | $17.29M derived: sum of 2 quarters · filed 2019-02-13 | $5.20M derived: sum of 3 quarters · filed 2019-02-13 | -$561.00K derived: sum of 4 quarters · filed 2019-02-13 | |||
| 2016-12-31 | $20.49M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $8.40M derived: sum of 2 quarters · filed 2019-02-13 | $2.64M derived: sum of 3 quarters · filed 2019-02-13 | $0.00 10-K · filed 2019-02-13 | -$31.15M 10-K · filed 2017-02-23 | ||
| 2016-09-30 | -$12.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-30 | -$17.85M derived: sum of 2 quarters · filed 2017-10-30 | -$20.49M 10-Q · filed 2017-10-30 | -$17.34M derived: sum of 4 quarters · filed 2018-02-15 | |||
| 2016-06-30 | -$5.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-28 | -$8.40M 10-Q · filed 2017-07-28 | -$5.25M derived: sum of 3 quarters · filed 2018-02-15 | -$17.80M derived: sum of 4 quarters · filed 2018-02-15 | |||
| 2016-03-31 | -$2.64M 10-Q · filed 2017-04-28 | $508.00K derived: sum of 2 quarters · filed 2018-02-15 | -$12.04M derived: sum of 3 quarters · filed 2018-02-15 | -$14.32M derived: sum of 4 quarters · filed 2018-02-15 | |||
| 2015-12-31 | $3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | -$9.41M derived: sum of 2 quarters · filed 2018-02-15 | -$11.69M derived: sum of 3 quarters · filed 2018-02-15 | -$11.69M 10-K · filed 2018-02-15 | |||
| 2015-09-30 | -$12.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-31 | -$14.83M derived: sum of 2 quarters · filed 2016-10-31 | -$14.83M 10-Q · filed 2016-10-31 | -$16.47M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-06-30 | -$2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | -$2.28M 10-Q · filed 2016-08-01 | -$3.92M derived: sum of 3 quarters · filed 2017-02-23 | -$3.92M derived: sum of 4 quarters · filed 2017-02-23 | |||
| 2015-03-31 | $0.00 10-Q · filed 2016-05-03 | $21.97M 10-Q · filed 2015-05-04 | -$1.64M derived: sum of 2 quarters · filed 2017-02-23 | -$1.64M derived: sum of 3 quarters · filed 2017-02-23 | -$1.64M derived: sum of 4 quarters · filed 2017-02-23 | ||
| 2014-12-31 | -$1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | -$1.64M derived: sum of 2 quarters · filed 2017-02-23 | -$1.64M derived: sum of 3 quarters · filed 2017-02-23 | -$1.64M 10-K · filed 2017-02-23 | |||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-30 | $0.00 derived: sum of 2 quarters · filed 2015-10-30 | $0.00 10-Q · filed 2015-10-30 | -$8.96M derived: sum of 4 quarters · filed 2016-02-16 | |||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $0.00 10-Q · filed 2015-08-04 | -$8.96M derived: sum of 3 quarters · filed 2016-02-16 | -$16.19M derived: sum of 4 quarters · filed 2016-02-16 | |||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-04 | -$8.96M derived: sum of 2 quarters · filed 2016-02-16 | -$16.19M derived: sum of 3 quarters · filed 2016-02-16 | -$20.91M derived: sum of 4 quarters · filed 2016-02-16 | |||
| 2013-12-31 | -$8.96M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-16 | -$16.19M derived: sum of 2 quarters · filed 2016-02-16 | -$20.91M derived: sum of 3 quarters · filed 2016-02-16 | -$27.88M 10-K · filed 2016-02-16 | |||
| 2013-09-30 | -$7.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | -$11.95M derived: sum of 2 quarters · filed 2014-11-06 | -$18.92M 10-Q · filed 2014-11-06 | -$23.89M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2013-06-30 | -$4.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$11.70M 10-Q · filed 2014-07-31 | -$16.66M derived: sum of 3 quarters · filed 2015-02-13 | $2.26M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2013-03-31 | -$6.97M 10-Q · filed 2014-05-05 | -$11.95M derived: sum of 2 quarters · filed 2015-02-13 | $6.98M derived: sum of 3 quarters · filed 2015-02-13 | $4.99M derived: sum of 4 quarters · filed 2015-02-13 | |||
| 2012-12-31 | -$4.97M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $13.96M derived: sum of 2 quarters · filed 2015-02-13 | $11.97M derived: sum of 3 quarters · filed 2015-02-13 | $18.11M 10-K · filed 2015-02-13 | |||
| 2012-09-30 | $18.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $16.94M derived: sum of 2 quarters · filed 2013-11-07 | $23.07M 10-Q · filed 2013-11-07 | $24.37M derived: sum of 4 quarters · filed 2014-02-11 | |||
| 2012-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-02 | $4.15M 10-Q · filed 2013-08-02 | $5.45M derived: sum of 3 quarters · filed 2014-02-11 | -$7.07M derived: sum of 4 quarters · filed 2014-02-11 | |||
| 2012-03-31 | $6.14M 10-Q · filed 2013-05-08 | $7.44M derived: sum of 2 quarters · filed 2014-02-11 | -$5.08M derived: sum of 3 quarters · filed 2014-02-11 | ||||
| 2011-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-11 | -$11.22M derived: sum of 2 quarters · filed 2014-02-11 | -$12.70M 10-K · filed 2014-02-11 | ||||
| 2011-09-30 | -$12.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | -$13.99M 10-Q · filed 2012-11-06 | |||||
| 2011-06-30 | -$1.48M 10-Q · filed 2012-08-08 | ||||||
| 2010-12-31 | $0.00 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |